On February 15th 2013 recruitment started for the DEEP-3 study (multi-centre, long-term observational safety study to evaluate the nature and incidence of adverse effects of deferiprone treatment in patients with beta-thalassaemia major aged from 1 month to less than 18 years). The first patient was enrolled at the ‘Agia Sofia’ Children’s Hospital, University of Athens in Greece.
The DEEP project has received research funding from the European Union under the 7th Framework Programme
